NK cells and cancer: You can teach innate cells new tricks

Nature Reviews Cancer

Volumn 16, Issue 1, 2016, Pages 7-19

  Morvan, Maelig G ^a   Lanier, Lewis L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR; EPITHELIAL CELL ADHESION MOLECULE; GAMMA INTERFERON; IMMUNOGLOBULIN E RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 22; INTERLEUKIN 5; MELANOCYTE PROTEIN PMEL 17; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2A; NATURAL KILLER CELL RECEPTOR NKG2D; PROGRAMMED DEATH 1 RECEPTOR; PROSTAGLANDIN E2; PROSTATE STEM CELL ANTIGEN; UNCLASSIFIED DRUG; LIGAND;

ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; HUMAN; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; INTRACELLULAR SIGNALING; LYMPHOID CELL; LYMPHOKINE ACTIVATED KILLER CELL; MACROPHAGE ACTIVATION; MAJOR HISTOCOMPATIBILITY COMPLEX; NATURAL KILLER CELL; NATURAL KILLER T CELL; NEOPLASM; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; TH1 CELL; TUMOR GROWTH; IMMUNOLOGY; NEOPLASMS; PATHOLOGY; PHYSIOLOGY;

HUMANS; KILLER CELLS, NATURAL; LIGANDS; NEOPLASMS; RECEPTORS, NATURAL KILLER CELL;

EID: 84951310757     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc.2015.5     Document Type: Review

References (189)

1. Artis, D., Spits, H. The biology of innate lymphoid cells. Nature 517, 293-301 (2015).
2. Orange, J. S. Natural killer cell deficiency. J. Allergy Clin. Immunol. 132, 515-525 (2013).
3. Lanier, L. L. Up on the tightrope: natural killer cell activation and inhibition. Nat. Immunol. 9, 495-502 (2008).
4. Campbell, K. S., Purdy, A. K. Structure/function of human killer cell immunoglobulin-like receptors: lessons from polymorphisms, evolution, crystal structures and mutations. Immunology 132, 315-325 (2011).
5. Schenkel, A. R., Kingry, L. C., Slayden, R. A. The Ly49 gene family. A brief guide to the nomenclature, genetics, and role in intracellular infection. Front. Immunol. 4, 90 (2013).
6. Lazetic, S., Chang, C., Houchins, J. P., Lanier, L. L., Phillips, J. H. Human natural killer cell receptors involved in MHC class I recognition are disulfide-linked heterodimers of CD94 and NKG2 subunits. J. Immunol. 157, 4741-4745 (1996).
7. Wada, H., Matsumoto, N., Maenaka, K., Suzuki, K., Yamamoto, K. The inhibitory NK cell receptor CD94/NKG2A and the activating receptor CD94/NKG2C bind the top of HLA-E through mostly shared but partly distinct sets of HLA-E residues. Eur. J. Immunol. 34, 81-90 (2004).
8. Braud, V. M. et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 391, 795-799 (1998).
9. Lee, N. et al. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc. Natl Acad. Sci. USA 95, 5199-5204 (1998).
10. Vance, R. E., Kraft, J. R., Altman, J. D., Jensen, P. E., Raulet, D. H. Mouse CD94/NKG2A Is a natural killer cell receptor for the nonclassical major histocompatibility complex (MHC) Class I molecule Qa-1b. J. Exp. Med. 188, 1841-1848 (1998).
11. Lopez-Vergès, S. et al. Expansion of a unique CD57+NKG2Chi natural killer cell subset during acute human cytomegalovirus infection. Proc. Natl Acad. Sci. USA 108, 14725-14732 (2011).
12. Cassidy, S. A., Cheent, K. S., Khakoo, S. I. Effects of peptide on NK cell-mediated MHC I recognition. Front. Immunol. 5, 133 (2014).
13. Tripathy, S. K., Smith, H. R. C., Holroyd, E. A., Pingel, J. T., Yokoyama, W. M. Expression of m157, a murine cytomegalovirus-encoded putative major histocompatibility class I (MHC-I)-like protein, is independent of viral regulation of host MHC-I. J. Virol. 80, 545-550 (2006).
14. Vivier, E. et al. Innate or adaptive immunity The example of natural killer cells. Science 331, 44-49 (2011).
15. Bauer, S. et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285, 727-729 (1999).
16. Lanier, L. L. NKG2D receptor and its ligands in host defense. Cancer Immunol. Res. 3, 575-582 (2015).
17. Raulet, D. H., Gasser, S., Gowen, B. G., Deng, W., Jung, H. Regulation of ligands for the NKG2D activating receptor. Annu. Rev. Immunol. 31, 413-441 (2013).
18. Kruse, P. H., Matta, J., Ugolini, S., Vivier, E. Natural cytotoxicity receptors and their ligands. Immunol. Cell Biol. 92, 221-229 (2014).
19. Pende, D. et al. Identification and molecular characterization of Nkp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J. Exp. Med. 190, 1505-1516 (1999).
20. Pessino, A. et al. Molecular cloning of NKp46: a novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity. J. Exp. Med. 188, 953-960 (1998).
21. Cantoni, C. et al. NKp44, a triggering receptor involved in tumor cell lysis by activated human natural killer cells, is a novel member of the immunoglobulin superfamily. J. Exp. Med. 189, 787-796 (1999).
22. Walzer, T. et al. Identification, activation, and selective in vivo ablation of mouse NK cells via NKp46. Proc. Natl Acad. Sci. USA 104, 3384-3389 (2007).
23. Hollyoake, M., Campbell, R. D., Aguado, B. NKp30 (NCR3) is a pseudogene in 12 inbred and wild mouse strains, but an expressed gene in Mus caroli. Mol. Biol. Evol. 22, 1661-1672 (2005).
24. Martinet, L., Smyth, M. J. Balancing natural killer cell activation through paired receptors. Nat. Rev. Immunol. 15, 243-254 (2015).
25. Lakshmikanth, T. et al. NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J. Clin. Invest. 119, 1251-1263 (2009).
26. Iguchi-Manaka, A. et al. Accelerated tumor growth in mice deficient in DNAM-1 receptor. J. Exp. Med. 205, 2959-2964 (2008).
27. Gilfillan, S. et al. DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. J. Exp. Med. 205, 2965-2973 (2008).
28. Chan, C. J. et al. The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions. Nat. Immunol. 15, 431-438 (2014).
29. Johnston, R. J. et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8+ T cell effector function. Cancer Cell 26, 923-937 (2014).
30. Bruhns, P. Properties of mouse and human IgG receptors and their contribution to disease models. Blood 119, 5640-5649 (2012).
31. Battella, S., Cox, M. C., Santoni, A., Palmieri, G. Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions. J. Leukoc. Biol., http://dx.doi.org/10.1189/jlb.5VMR0415-141R (2015).
32. Voskoboinik, I., Whisstock, J. C., Trapani, J. A. Perforin and granzymes: function, dysfunction and human pathology. Nat. Rev. Immunol. 15, 388-400 (2015).
33. Krzewski, K., Coligan, J. E. Human NK cell lytic granules and regulation of their exocytosis. NK Cell Biol. 3, 335 (2012).
34. Wallin, R. P. A., Screpanti, V., Michaëlsson, J., Grandien, A., Ljunggren, H.-G. Regulation of perforin-independent NK cell-mediated cytotoxicity. Eur. J. Immunol. 33, 2727-2735 (2003).
35. Smyth, M. J. et al. Activation of NK cell cytotoxicity. Mol. Immunol. 42, 501-510 (2005).
36. Cretney, E. et al. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J. Immunol. 168, 1356-1361 (2002).
37. Cooper, M. A. et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset. Blood 97, 3146-3151 (2001).
38. Maghazachi, A. A. in The Chemokine System in Experimental and Clinical Hematology (ed. Bruserud, O.) 37-58 (Springer, 2010).
39. O'Sullivan, T. et al. Cancer immunoediting by the innate immune system in the absence of adaptive immunity. J. Exp. Med. 209, 1869-1882 (2012).
40. Roder, J. C. et al. A new immunodeficiency disorder in humans involving NK cells. Nature 284, 553-555 (1980).
41. Sullivan, J. L., Byron, K. S., Brewster, F. E., Purtilo, D. T. Deficient natural killer cell activity in x-linked lymphoproliferative syndrome. Science 210, 543-545 (1980).
42. Talmadge, J. E., Meyers, K. M., Prieur, D. J., Starkey, J. R. Role of natural killer cells in tumor growth and metastasis: C57BL/6 normal and beige mice. J. Natl Cancer Inst. 65, 929-935 (1980).
43. Gorelik, E., Wiltrout, R. H., Okumura, K., Habu, S., Herberman, R. B. Role of NK cells in the control of metastatic spread and growth of tumor cells in mice. Int. J. Cancer 30, 107-112 (1982).
44. Nakajima, T., Mizushima, N., Nakamura, J., Kanai, K. Surface markers of NK cells in peripheral blood of patients with cirrhosis and hepatocellular carcinoma. Immunol. Lett. 13, 7-10 (1986).
45. Pross, H. F., Lotzová, E. Role of natural killer cells in cancer. Nat. Immunol. 12, 279-292 (1993).
46. Schantz, S. P., Shillitoe, E. J., Brown, B., Campbell, B. Natural killer cell activity and head and neck cancer: a clinical assessment. J. Natl Cancer Inst. 77, 869-875 (1986).
47. Strayer, D. R., Carter, W. A., Brodsky, I. Familial occurrence of breast cancer is associated with reduced natural killer cytotoxicity. Breast Cancer Res. Treat. 7, 187-192 (1986).
48. Hersey, P., Edwards, A., Honeyman, M., McCarthy, W. H. Low natural-killer-cell activity in familial melanoma patients and their relatives. Br. J. Cancer 40, 113-122 (1979).
49. Imai, K., Matsuyama, S., Miyake, S., Suga, K., Nakachi, K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 356, 1795-1799 (2000).
50. Spinner, M. A. et al. GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics and immunity. Blood 123, 809-821 (2013).
51. Gineau, L. et al. Partial MCM4 deficiency in patients with growth retardation, adrenal insufficiency, and natural killer cell deficiency. J. Clin. Invest. 122, 821-832 (2012).
52. Smyth, M. J., Hayakawa, Y., Takeda, K., Yagita, H. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat. Rev. Cancer 2, 850-861 (2002).
53. Bezman, N. A. et al. Molecular definition of the identity and activation of natural killer cells. Nat. Immunol. 13, 1000-1009 (2012).
54. Hudspeth, K., Silva-Santos, B., Mavilio, D. Natural cytotoxicity receptors: broader expression patterns and functions in innate and adaptive immune cells. NK Cell Biol. 4, 69 (2013).
55. Robinette, M. L. et al. Transcriptional programs define molecular characteristics of innate lymphoid cell classes and subsets. Nat. Immunol. 16, 306-317 (2015).
56. Albertsson, P. A. et al. NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity. Trends Immunol. 24, 603-609 (2003).
57. Bix, M. et al. Rejection of class I MHC-deficient haemopoietic cells by irradiated MHC-matched mice. Nature 349, 329-331 (1991).
58. Nausch, N., Cerwenka, A. NKG2D ligands in tumor immunity. Oncogene 27, 5944-5958 (2008).
59. Cerwenka, A., Baron, J. L., Lanier, L. L. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc. Natl Acad. Sci. USA 98, 11521-11526 (2001).
60. Diefenbach, A., Jensen, E. R., Jamieson, A. M., Raulet, D. H. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 413, 165-171 (2001).
61. Guerra, N. et al. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 28, 571-580 (2008).
62. Hayakawa, Y. et al. Cutting edge: tumor rejection mediated by NKG2D receptor-ligand interaction is dependent upon perforin. J. Immunol. 169, 5377-5381 (2002).
63. Groh, V., Wu, J., Yee, C., Spies, T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419, 734-738 (2002).
64. Kaiser, B. K. et al. Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands. Nature 447, 482-486 (2007).
65. Salih, H. R., Rammensee, H.-G., Steinle, A. Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J. Immunol. 169, 4098-4102 (2002).
66. Wu, J. D. et al. Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J. Clin. Invest. 114, 560-568 (2004).
67. Fernández-Messina, L. et al. Differential mechanisms of shedding of the glycosylphosphatidylinositol (GPI)-anchored NKG2D ligands. J. Biol. Chem. 285, 8543-8551 (2010).
68. Salih, H. R., Goehlsdorf, D., Steinle, A. Release of MICB molecules by tumor cells: mechanism and soluble MICB in sera of cancer patients. Hum. Immunol. 67, 188-195 (2006).
69. Salih, H. R., Holdenrieder, S., Steinle, A. Soluble NKG2D ligands: prevalence, release, and functional impact. Front. Biosci. 13, 3448-3456 (2008).
70. Holdenrieder, S. et al. Soluble MICA in malignant diseases. Int. J. Cancer 118, 684-687 (2006).
71. Crane, C. A. et al. Immune evasion mediated by tumor-derived lactate dehydrogenase induction of NKG2D ligands on myeloid cells in glioblastoma patients. Proc. Natl Acad. Sci. USA 111, 12823-12828 (2014).
72. Champsaur, M., Lanier, L. L. Effect of NKG2D ligand expression on host immune responses. Immunol. Rev. 235, 267-285 (2010).
73. Oppenheim, D. E. et al. Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nat. Immunol. 6, 928-937 (2005).
74. Deng, W. et al. A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection. Science 348, 136-139 (2015).
75. Kopp, H.-G., Placke, T., Salih, H. R. Platelet-derived transforming growth factor-down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. Cancer Res. 69, 7775-7783 (2009).
76. Placke, T., Kopp, H.-G., Salih, H. R. The wolf in sheep's clothing. Oncoimmunology 1, 557-559 (2012).
77. Placke, T., Salih, H. R., Kopp, H.-G. GITR ligand provided by thrombopoietic cells inhibits NK cell antitumor activity. J. Immunol. 189, 154-160 (2012).
78. Placke, T., Kopp, H.-G., Salih, H. R. Modulation of natural killer cell anti-tumor reactivity by platelets. J. Innate Immun. 3, 374-382 (2011).
79. Wilson, E. B. et al. Human tumour immune evasion via TGF-blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity. PLoS ONE 6, e22842 (2011).
80. Holt, D., Ma, X., Kundu, N., Fulton, A. Prostaglandin E2 (PGE2) suppresses natural killer cell function primarily through the PGE2 receptor EP4. Cancer Immunol. Immunother. 60, 1577-1586 (2011).
81. Pietra, G. et al. Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity. Cancer Res. 72, 1407-1415 (2012).
82. Hoskin, D., Mader, J., Furlong, S., Conrad, D., Blay, J. Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review). Int. J. Oncol. 32, 527-535 (2008).
83. Richards, J. O. et al. Tumor growth impedes natural-killer-cell maturation in the bone marrow. Blood 108, 246-252 (2006).
84. Mocellin, S., Marincola, F. M., Young, H. A. Interleukin-10 and the immune response against cancer: a counterpoint. J. Leukoc. Biol. 78, 1043-1051 (2005).
85. Park, J. Y. et al. IL-15-induced IL-10 increases the cytolytic activity of human natural killer cells. Mol. Cells 32, 265-272 (2011).
86. Moretta, A. et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu. Rev. Immunol. 19, 197-223 (2001).
87. Byrd, A., Hoffmann, S. C., Jarahian, M., Momburg, F., Watzl, C. Expression analysis of the ligands for the natural killer cell receptors NKp30 and NKp44. PLoS ONE 2, e1339 (2007).
88. Cagnano, E. et al. Expression of ligands to NKp46 in benign and malignant melanocytes. J. Invest. Dermatol. 128, 972-979 (2007).
89. Brandt, C. S. et al. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J. Exp. Med. 206, 1495-1503 (2009).
90. Li, Y., Wang, Q., Mariuzza, R. A. Structure of the human activating natural cytotoxicity receptor NKp30 bound to its tumor cell ligand B7-H6. J. Exp. Med. 208, 703-714 (2011).
91. Matta, J. et al. Induction of B7-H6, a ligand for the natural killer cell-activating receptor NKp30, in inflammatory conditions. Blood 122, 394-404 (2013).
92. Halfteck, G. G. et al. Enhanced in vivo growth of lymphoma tumors in the absence of the NK-activating receptor NKp46/NCR1. J. Immunol. 182, 2221-2230 (2009).
93. Glasner, A. et al. Recognition and prevention of tumor metastasis by the NK receptor NKp46/NCR1. J. Immunol. 188, 2509-2515 (2012).
94. Alvarez-Breckenridge, C. A. et al. NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors. Nat. Med. 18, 1827-1834 (2012).
95. Schreiber, R. D., Old, L. J., Smyth, M. J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331, 1565-1570 (2011).
96. Smyth, M. J. et al. NKG2D function protects the host from tumor initiation. J. Exp. Med. 202, 583-588 (2005).
97. Elboim, M. et al. Tumor immunoediting by NKp46. J. Immunol. 184, 5637-5644 (2010).
98. Alvarez, I. B. et al. Role played by the programmed death-1-programmed death ligand pathway during innate immunity against Mycobacterium tuberculosis. J. Infect. Dis. 202, 524-532 (2010).
99. Norris, S. et al. PD-1 expression on natural killer cells and CD8+ T cells during chronic HIV-1 infection. Viral Immunol. 25, 329-332 (2012).
100. Stojanovic, A., Fiegler, N., Brunner-Weinzierl, M., Cerwenka, A. CTLA-4 is expressed by activated mouse NK cells and inhibits NK cell IFN-production in response to mature dendritic cells. J. Immunol. 192, 4184-4191 (2014).
101. Benson, D. M. et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 116, 2286-2294 (2010).
102. Boyerinas, B. et al. Antibody dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody, avelumab (MSB0010718C), on human tumor cells. Cancer Immunol. Res. 3, 1148-1157 (2015).
103. Lang, S., Vujanovic, N. L., Wollenberg, B., Whiteside, T. L. Absence of B7.1-CD28/CTLA-4-mediated co-stimulation in human NK cells. Eur. J. Immunol. 28, 780-786 (1998).
104. Chambers, B. J., Salcedo, M., Ljunggren, H.-G. Triggering of natural killer cells by the costimulatory molecule CD80 (B7-1). Immunity 5, 311-317 (1996).
105. Contardi, E. et al. CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction. Int. J. Cancer 117, 538-550 (2005).
106. Laurent, S. et al. The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-production. J. Transl Med. 11, 108 (2013).
107. Jarahian, M. et al. Activation of natural killer cells by Newcastle disease virus hemagglutinin-neuraminidase. J. Virol. 83, 8108-8121 (2009).
108. Bhat, R., Dempe, S., Dinsart, C., Rommelaere, J. Enhancement of NK cell antitumor responses using an oncolytic parvovirus. Int. J. Cancer 128, 908-919 (2011).
109. Zamarin, D. et al. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci. Transl Med. 6, 226-32 (2014).
110. Romagné, F. et al. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood 114, 2667-2677 (2009).
111. Vahlne, G. et al. In vivo tumor cell rejection induced by NK cell inhibitory receptor blockade: maintained tolerance to normal cells even in the presence of IL-2. Eur. J. Immunol. 40, 813-823 (2010).
112. Kohrt, H. E. et al. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood 123, 678-686 (2014).
113. This article reports that KIR blockade enhances the ADCC activity of NK cells in preclinical models. 113. Vey, N. et al. A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. Blood 120, 4317-4323 (2012).
114. Benson, D. M. et al. A Phase I trial of the anti-KIR antibody IPH2101 and lenalidomide in patients with relapsed/refractory multiple myeloma. Clin. Cancer Res. 21, 4055-4061 (2015).
115. Benson, D. M. et al. A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood 120, 4324-4333 (2012).
116. Seymour, L., Tinker, A., Hirte, H., Wagtmann, N., Dodion, P. Abstract O3.2. Phase I and dose ranging, phase II studies with IPH2201, a humanized monoclonal antibody targeting HLA-E receptor CD94/NKG2A. Ann. Oncol. 26 (Suppl 2), ii3-ii3 (2015).
117. Ndhlovu, L. C. et al. Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. Blood 119, 3734-3743 (2012).
118. Sun, H., Sun, C., Xiao, W. Expression regulation of co-inhibitory molecules on human natural killer cells in response to cytokine stimulations. Cytokine 65, 33-41 (2014).
119. Jing, W. et al. Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma. J. Immunother. Cancer 3, 2 (2015).
120. Ngiow, S. F., Teng, M. W. L., Smyth, M. J. Prospects for TIM3-targeted antitumor immunotherapy. Cancer Res. 71, 6567-6571 (2011).
121. Woo, S.-R. et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 72, 917-927 (2012).
122. Bartkowiak, T., Curran, M. A. 4-1BB agonists: multi-potent potentiators of tumor immunity. Front. Oncol. 5, 117 (2015).
123. Baessler, T. et al. CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells. Blood 115, 3058-3069 (2010).
124. Kohrt, H. E. et al. Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J. Clin. Invest. 122, 1066-1075 (2012).
125. Kohrt, H. E. et al. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood 117, 2423-2432 (2011).
126. Ascierto, P. A., Simeone, E., Sznol, M., Fu, Y.-X., Melero, I. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin. Oncol. 37, 508-516 (2010).
127. Melero, I., Hirschhorn-Cymerman, D., Morales-Kastresana, A., Sanmamed, M. F., Wolchok, J. D. Agonist antibodies to TNFR molecules that costimulate T and NK cells. Clin. Cancer Res. 19, 1044-1053 (2013).
128. Rosenberg, S. A. et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med. 313, 1485-1492 (1985).
129. Ruggeri, L. et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295, 2097-2100 (2002).
130. Miller, J. S. et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105, 3051-3057 (2005).
131. Ishikawa, E. et al. Autologous natural killer cell therapy for human recurrent malignant glioma. Anticancer Res. 24, 1861-1871 (2004).
132. Shah, N. N. et al. Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation. Blood 125, 784-792 (2015).
133. Cooper, M. A. et al. Cytokine-induced memory-like natural killer cells. Proc. Natl Acad. Sci. USA 106, 1915-1919 (2009).
134. Ni, J., Miller, M., Stojanovic, A., Cerwenka, A. Toward the next generation of NK cell-based adoptive cancer immunotherapy. Oncoimmunology 2 (2013).
135. Ni, J., Miller, M., Stojanovic, A., Garbi, N., Cerwenka, A. Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors. J. Exp. Med. 209, 2351-2365 (2012).
136. Ardolino, M., Hsu, J., Raulet, D. H. Cytokine treatment in cancer immunotherapy. Oncotarget 6, 19346-19347 (2015).
137. Ardolino, M. et al. Cytokine therapy reverses NK cell anergy in MHC-deficient tumors. J. Clin. Invest. 124, 4781-4794 (2014).
138. Floros, T., Tarhini, A. A. Anticancer cytokines: biology and clinical effects of interferon-2, interleukin (IL)-2, IL-15, IL-21, and IL-12. Semin. Oncol. 42, 539-548 (2015).
139. Guo, Y. et al. IL-15 superagonist-mediated immunotoxicity: role of NK cells and IFN-. J. Immunol. 195, 2353-2364 (2015).
140. Glienke, W. et al. Advantages and applications of CAR-expressing natural killer cells. Exp. Pharmacol. Drug Discov. 6, 21 (2015).
141. Hermanson, D. L., Kaufman, D. S. Utilizing chimeric antigen receptors to direct natural killer cell activity. Front. Immunol. 6, 195 (2015).
142. Boissel, L., Betancur, M., Wels, W. S., Tuncer, H., Klingemann, H. Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells. Leuk. Res. 33, 1255-1259 (2009).
143. Müller, T. et al. Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells. Cancer Immunol. Immunother. 57, 411-423 (2007).
144. Esser, R. et al. NK cells engineered to express a GD2-specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin. J. Cell. Mol. Med. 16, 569-581 (2012).
145. Ahmed, M., Cheung, N.-K. V. Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy. FEBS Lett. 588, 288-297 (2014).
146. Uherek, C. et al. Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood 100, 1265-1273 (2002).
147. Liu, H. et al. Specific growth inhibition of ErbB2-expressing human breast cancer cells by genetically modified NK92 cells. Oncol. Rep. 33, 95-102 (2015).
148. Schönfeld, K. et al. Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor. Mol. Ther. 23, 330-338 (2015).
149. Sahm, C., Schönfeld, K., Wels, W. S. Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor. Cancer Immunol. Immunother. 61, 1451-1461 (2012).
150. Zhang, G. et al. Retargeting NK-92 for anti-melanoma activity by a TCR-like single-domain antibody. Immunol. Cell Biol. 91, 615-624 (2013).
151. Töpfer, K. et al. DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy. J. Immunol. 194, 3201-3212 (2015).
152. Jiang, H. et al. Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells. Mol. Oncol. 8, 297-310 (2014).
153. Knorr, D. A., Kaufman, D. S. Pluripotent stem cell-derived natural killer cells for cancer therapy. Transl. Res. J. Lab. Clin. Med. 156, 147-154 (2010).
154. Eguizabal, C. et al. Natural killer cells for cancer immunotherapy: pluripotent stem cells-derived NK cells as an immunotherapeutic perspective. NK Cell Biol. 5, 439 (2014).
155. Chu, J. et al. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia 28, 917-927 (2014).
156. Ni, Z. et al. Functional chimeric antigen receptor-expressing natural killer cells derived from human pluripotent stem cells. Blood 122, 896-896 (2013).
157. Imai, C., Iwamoto, S., Campana, D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 106, 376-383 (2005).
158. Li, L. et al. Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method. Cancer Gene Ther. 17, 147-154 (2009).
159. Shimasaki, N. et al. A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies. Cytotherapy 14, 830-840 (2012).
160. Alsamah, W., Romia, Y. Modification of natural killer cells to target tumors. Int. J. Pharm. Clin. Res. 6, 97-100 (2014).
161. Altvater, B. et al. 2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells. Clin. Cancer Res. 15, 4857-4866 (2009).
162. Müller, N. et al. Engineering NK cells modified with an EGFRvIII-specific chimeric antigen receptor to overexpress CXCR4 improves immunotherapy of CXCL12/SDF-1-secreting glioblastoma. J. Immunother. 38, 197-210 (2015).
163. Han, J. et al. CAR-engineered NK cells targeting wild-type EGFR and EGFRvIII enhance killing of glioblastoma and patient-derived glioblastoma stem cells. Sci. Rep. 5, 11483 (2015).
164. Boissel, L. et al. Retargeting NK-92 cells by means of CD19-and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity. Oncoimmunology 2 (2013).
165. Klingemann, H. Are natural killer cells superior CAR drivers OncoImmunology 3, e28147 (2014).
166. Sentman, C. L., Meehan, K. R. NKG2D CARs as cell therapy for cancer. Cancer J. 20, 156-159 (2014).
167. Barber, A., Rynda, A., Sentman, C. L. Chimeric NKG2D expressing T cells eliminate immunosuppression and activate immunity within the ovarian tumor microenvironment. J. Immunol. 183, 6939-6947 (2009).
168. Roy, S. et al. NK cells lyse T regulatory cells that expand in response to an intracellular pathogen. J. Immunol. 180, 1729-1736 (2008).
169. Zhang, T., Sentman, C. L. Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells. Cancer Res. 71, 2066-2076 (2011).
170. Lehner, M. et al. Redirecting T cells to Ewing's sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection. PLoS ONE 7, e31210 (2012).
171. VanSeggelen, H. et al. T cells engineered with chimeric antigen receptors targeting NKG2D ligands display lethal toxicity in mice. Mol. Ther. http://dx.doi.org/10.1038/mt.2015.119 (2015).
172. Kudo, K. et al. T lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing. Cancer Res. 74, 93-103 (2014).
173. Tal, Y. et al. An NCR1-based chimeric receptor endows T-cells with multiple anti-tumor specificities. Oncotarget 5, 10949-10958 (2014).
174. Zhang, T., Wu, M.-R., Sentman, C. L. An NKp30-based chimeric antigen receptor promotes T cell effector functions and antitumor efficacy in vivo. J. Immunol. 189, 2290-2299 (2012).
175. Asano, R. et al. Construction and humanization of a functional bispecific EGFR × CD16 diabody using a refolding system. FEBS J. 279, 223-233 (2012).
176. Reusch, U. et al. A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells. MAbs 6, 727-738 (2014).
177. Kellner, C. et al. Heterodimeric bispecific antibody-derivatives against CD19 and CD16 induce effective antibody-dependent cellular cytotoxicity against B-lymphoid tumor cells. Cancer Lett. 303, 128-139 (2011).
178. Bruenke, J. et al. A recombinant bispecific single-chain Fv antibody against HLA class II and FcRIII (CD16) triggers effective lysis of lymphoma cells. Br. J. Haematol. 125, 167-179 (2004).
179. Hartmann, F. et al. Anti-CD16/CD30 bispecific antibody treatment for Hodgkin's disease role of infusion schedule and costimulation with cytokines. Clin. Cancer Res. 7, 1873-1881 (2001).
180. Kasuya, K. et al. Bispecific anti-HER2 and CD16 single-chain antibody production prolongs the use of stem cell-like cell transplantation against HER2-overexpressing cancer. Int. J. Mol. Med. 25, 209-215 (2010).
181. Shahied, L. S. et al. Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format. J. Biol. Chem. 279, 53907-53914 (2004).
182. Singer, H. et al. Effective elimination of acute myeloid leukemic cells by recombinant bispecific antibody derivatives directed against CD33 and CD16: J. Immunother. 33, 599-608 (2010).
183. Wiernik, A. et al. Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 × 33 bispecific killer cell engager and ADAM17 inhibition. Clin. Cancer Res. 19, 3844-3855 (2013).
184. Vallera, D. A. et al. Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells. Cancer Biother. Radiopharm. 28, 274-282 (2013).
185. Spear, P., Wu, M.-R., Sentman, M.-L., Sentman, C. L. NKG2D ligands as therapeutic targets. Cancer Immun. 13, 8 (2013).
186. Strandmann, E. P. von et al. A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo. Blood 107, 1955-1962 (2006).
187. Rothe, A. et al. The bispecific immunoligand ULBP2-aCEA redirects natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinoma. Int. J. Cancer 134, 2829-2840 (2014).
188. Germain, C. et al. MHC Class I-related chain A conjugated to antitumor antibodies can sensitize tumor cells to specific lysis by natural killer cells. Clin. Cancer Res. 11, 7516-7522 (2005).
189. Stamova, S. et al. Simultaneous engagement of the activatory receptors NKG2D and CD3 for retargeting of effector cells to CD33-positive malignant cells. Leukemia 25, 1053-1056 (2011).